Retention, efficacy, tolerability, and quality of life during long-term adjunctive brivaracetam treatment by number of lifetime antiseizure medications: A post hoc analysis of phase 3 trials in adults with focal seizures

•Data from two trials of adjunctive brivaracetam (BRV) in adults with focal seizures.•Post hoc outcomes assessed by the number of lifetime antiseizure medications (ASMs)•Generally higher retention and efficacy of BRV in patients exposed to fewer ASMs.•Patients with fewer ASMs were less likely to discontinue BRV due to adverse events.•Patients with ≥7-lifetime ASMs could still benefit from long-term BRV treatment.